[Treatment of hemophilia with immunologic inhibitor of factor VIII by using "activated" coagulant fractions].
Bleeding episodes in hemophiliacs with inhibitor to factor VIII are often dramatic situations. High level inhibitors do not respond to massive amount of factor VIII and are often refractory to immunosuppressive drugs such as cyclophosphamide. In this situation it has been proposed to use "activated prothrombin complex" to control bleeding in hemophilic patients with inhibitors. A plasmatic fraction "Auto IX" has been used successfully for the treatment of an intestinal hemorrhage in a patient with an inhibitor to F. VIII. Possible mechanisms of action as well as potential thrombotic danger of such concentrate are discussed.
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D001803:Blood Transfusion; D003029:Coagulants / Q000627:therapeutic use*; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D066298:In Vitro Techniques; D008297:Male; D008551:Melena / Q000209:etiology
D003029:Coagulants; D007166:Immunosuppressive Agents; D005169:Factor VIII
Traitement de l'hémophilie avec inhibiteur immunologique du facteur VIII par les fractions coagulantes "activées"